GFS & USAS: Strategic Plays Under Deal Baselines

67
Trading two strong setups where national security interest creates a clear floor under price. One is a mature semiconductor giant on discount, the other is an active domestic critical metals producer.

GlobalFoundries: Value Window Below Government Baseline
GFS sits below the 51 valuation benchmark from federal funding announcements. The market has treated it like a legacy cyclical drag, but the setup offers solid risk reward.

Massive federal alignment: Backed by 375M in direct awards and packaging expansion, the government is taking direct equity interest rather than free grants.

Deep cash cushion: Over 3.3B in liquid cash on the balance sheet limits balance sheet distress.

Proven foundry moat: High barrier to entry for automotive and aerospace defense silicon that cannot simply be offshored.

Core idea: GFS looks ready here. The downside is well protected by hard assets and federal backing. Buying equity or deep in the money leaps near current levels lets time do the heavy lifting.

Americas Gold and Silver: Accumulate on Pullbacks
USAS has run hard into the 5.50 zone, but it belongs on watchlists for any healthy pullback.

The real metal driver: Forget just gold and silver. USAS owns the Galena Complex in Idaho, which is the largest active producing antimony mine in the country. Antimony is a vital defense metal for munitions and grid power facing strict export bans.

The USAR connection: USAS formed a joint venture with US Antimony to build a dedicated domestic processing hub. USAS provides raw ore and captures 51 percent of downstream refining margins.

Turning cash flow positive: Full year silver guidance sits above 3.2M ounces, balance sheet debt was settled for equity, and H1 revenue surged over 100 percent.

Core idea: Do not chase green candles into resistance. Look for standard pullbacks to accumulate. The domestic antimony story gives it asymmetric buyout or contract potential as the critical mineral supply chain tightens.

免責聲明

這些資訊和出版物並非旨在提供,也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。